Efficacy, acceptability, and clinical effects of a low-dose injectable contraceptive combination of dihydroxyprogesterone acetophenide and estradiol enanthate

被引:7
作者
Coutinho, EM
Spinola, P
Tomaz, G
Morais, K
de Souza, RN
Neto, JSP
Leal, WD
Hippolito, SB
Abranches, AD
机构
[1] CEPARH, BR-40210341 Salvador, BA, Brazil
[2] Univ Fed Bahia, Salvador, BA, Brazil
[3] Univ Fed Paraiba, BR-58059900 Joao Pessoa, Paraiba, Brazil
[4] Univ Fed Rio Grande Norte, BR-59072970 Natal, RN, Brazil
[5] Univ Para, Belem, Para, Brazil
[6] Univ Fed Pernambuco, Recife, PE, Brazil
[7] Fed Univ Ceara, Fortaleza, Ceara, Brazil
[8] CEPECS, Belo Horizonte, MG, Brazil
关键词
injectable contraceptive; dihydroxyprogesterone acetophenide; estradiol enanthate;
D O I
10.1016/S0010-7824(00)00099-8
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
A total of 1,904 women, aged 15-38, used an injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide with 6 mg estradiol enanthate, given once during each menstrual cycle between the 7th and 10th day, and preferably on the 8th day of the cycle, Joy a total of 17,576 cycles. Of these 1,904 women, 1,197 completed 12 cycles of use of the injectable combination. One subject became pregnant during the trial, resulting in a cumulative pregnancy rare of 0.07%. Principal reasons for discontinuation were personal, non-medical reasons, such as lost to follow-up, no longer wished to continue, protocol violation, desire to change to another contraceptive method, moved away, or other personal reasons. Mean weight of 1,901 subjects at admission to the trial was 53.5 +/- 0.2 kg and this increased to 54.3 +/- 0.3 kg after 12 cycles of use. Approximately 50% of subjects experienced menstrual bleeding similar to normal throughout the study period. The most frequent menstrual abnormality was irregular bleeding, experienced by approximately one-third of subjects. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 8 条
[1]  
BENAGIANO G, 1977, REGULATION HUMAN FER, P323
[2]   Multicenter, double-blind, comparative clinical study on the efficacy and acceptability of a monthly injectable contraceptive combination of 150 mg dihydroxyprogesterone acetophenide and 10 mg estradiol enanthate compared to a monthly injectable contraceptive combination of 90 mg dihydroxyprogesterone acetophenide and 6 mg estradiol enanthate [J].
Coutinho, EM ;
Spinola, P ;
Barbosa, I ;
Gatto, M ;
Tomaz, G ;
Morais, K ;
Yazlle, ME ;
deSouza, RN ;
Neto, JSP ;
Leal, WD ;
Leal, C ;
Hippolito, SB ;
Abranches, AD .
CONTRACEPTION, 1997, 55 (03) :175-181
[3]  
Hall P E, 1987, IPPF Med Bull, V21, P1
[4]   ONCE-A-MONTH INJECTABLE CONTRACEPTIVES - EFFICACY AND REASONS FOR DISCONTINUATION [J].
KOETSAWANG, S .
CONTRACEPTION, 1994, 49 (04) :387-398
[5]  
LANDE RE, 1995, POPULATION REPORTS K, V5
[6]   A COMPARATIVE-STUDY OF ONE-YEAR WEIGHT-GAIN AMONG USERS OF MEDROXYPROGESTERONE ACETATE, LEVONORGESTREL IMPLANTS, AND ORAL-CONTRACEPTIVES [J].
MOORE, LL ;
VALUCK, R ;
MCDOUGALL, C ;
FINK, W .
CONTRACEPTION, 1995, 52 (04) :215-219
[7]  
*WHO, 1991, SPEC PROGR RES DEV R
[8]   MULTICENTERED CLINICAL-STUDY OF THE METABOLIC EFFECT OF THE MONTHLY INJECTABLE CONTRACEPTIVE CONTAINING DIHYDROXYPROGESTERONE ACETOPHENIDE 150-MG + ESTRADIOL ENANTHATE 10-MG [J].
WIEMEYER, JCM ;
SAGASTA, CL ;
MATEO, JMR ;
LAVARELLO, ACM ;
DETORO, LAA ;
DIAZ, RS .
CONTRACEPTION, 1990, 42 (01) :13-28